HBM Healthcare Investments Valuation Multiples

Discover HBM Healthcare Investments' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Grupo Bolivar, FIBRA Macquarie, Generation Capital, L1 Group and more.

HBM Healthcare Investments Overview

About HBM Healthcare Investments

HBM Healthcare Investments Ltd is a Switzerland-based holding company. The firm actively invests in the human medicine, biotechnology, medical technology, and diagnostics sectors and related areas. The company holds and manages an international portfolio of companies.


Founded

2001

HQ

Switzerland

Employees

1

Financials (LTM)

Revenue: $102M
Net Income: $347M

EV

$2.2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

HBM Healthcare Investments Financials

HBM Healthcare Investments reported last 12-month revenue of $102M.

In the same LTM period, HBM Healthcare Investments generated $347M in net income.

Revenue (LTM)


HBM Healthcare Investments P&L

In the most recent fiscal year, HBM Healthcare Investments reported revenue of $340M and net income of $347M.

HBM Healthcare Investments is profitable as of last fiscal year, with net margin of 102%.

See analyst estimates for HBM Healthcare Investments
LTMLast FY202320242025202620272028
Revenue$102M$340M($44M)$20M$261M
Net Profit$347M$347M($46M)$17M$258M
Net Margin340%102%106%85%99%
Net Debt-$117M---

Financial data powered by Morningstar, Inc.

HBM Healthcare Investments Stock Performance

HBM Healthcare Investments has current market cap of $2B, and enterprise value of $2.2B.

Market Cap Evolution


HBM Healthcare Investments' stock price is $308.38.

HBM Healthcare Investments share price increased by 5.5% in the last 30 days, and by 43.2% in the last year.

HBM Healthcare Investments has an EPS (earnings per share) of $52.53.

See more trading valuation data for HBM Healthcare Investments
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2.2B$2B0.1%5.5%3.7%43.2%$52.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

HBM Healthcare Investments Valuation Multiples

HBM Healthcare Investments trades at 21.2x EV/Revenue multiple.

See NTM and 2027E valuation multiples for HBM Healthcare Investments

EV / Revenue (LTM)


HBM Healthcare Investments Financial Valuation Multiples

As of July 19, 2026, HBM Healthcare Investments has market cap of $2B and EV of $2.2B.

HBM Healthcare Investments has a P/E ratio of 5.9x.

LTMLast FY202320242025202620272028
EV/Revenue21.2x6.4x(49.6x)108.3x8.3x
P/E5.9x5.9x(44.0x)120.8x7.9x
EV/FCF-n/mn/mn/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified HBM Healthcare Investments Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

HBM Healthcare Investments Margins & Growth Rates

In the most recent fiscal year, HBM Healthcare Investments reported net margin of 102%.

See estimated margins and future growth rates for HBM Healthcare Investments

HBM Healthcare Investments Margins

Last FY202420252026202720282029
Net Margin102%85%99%99%
FCF Margin(1%)(14%)(1%)(1%)

HBM Healthcare Investments Growth Rates

23/2424/2525/2626/2727/2828/29
Revenue Growth(146%)1209%30%
Net Profit Growth(136%)1429%30%
FCF Growth37%19%3%

Data powered by FactSet, Inc. and Morningstar, Inc.

HBM Healthcare Investments Operational KPIs

HBM Healthcare Investments' revenue per employee in the last FY averaged $339.9M, while opex per employee averaged $3.2M for the same period.

Access forward-looking KPIs for HBM Healthcare Investments
Last FY202320242025202620272028
Revenue per Employee$339.9M---
Opex per Employee$3.2M---
G&A Expenses to Revenue1%(5%)13%1%
Opex to Revenue1%(6%)15%1%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

HBM Healthcare Investments Competitors

HBM Healthcare Investments competitors include Grupo Bolivar, FIBRA Macquarie, Generation Capital, L1 Group, Magellan Financial Group, FII Ancar IC, Bure Equity, MFF Capital, Israel Corp and L1 Long Short Fund.

Most HBM Healthcare Investments public comparables operate across Asset Management.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Grupo Bolivar0.4x---
FIBRA Macquarie10.8x10.7x14.2x14.1x
Generation Capital34.9x-10.9x-
L1 Group19.2x5.6x82.0x7.6x
Magellan Financial Group9.1x12.9x14.9x19.3x
FII Ancar IC----
Bure Equity75.2x-(4.3x)-
MFF Capital5.0x---

This data is available for Pro users. Sign up to see all HBM Healthcare Investments competitors and their valuation data.

Start Free Trial

Investments by HBM Healthcare Investments

HBM Healthcare Investments has invested in 80 companies to date.

Latest investment by HBM Healthcare Investments was on July 6th 2026. HBM Healthcare Investments invested in Fore Biotherapeutics in their $67M Series D round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by HBM Healthcare Investments

Fore Biotherapeutics
Lycia Therapeutics
CellCentric
SnapNurse
Description
Fore Biotherapeutics is a precision oncology biotech headquartered in Cambridge, Massachusetts. The company develops small-molecule therapies targeting undruggable mutations in RAS, PI3K, and MTAP pathways using functional genomics screening. Its lead program advances toward clinical trials for pancreatic and lung cancers. Fore Bio collaborates with academic labs and raised Series A funding in 2023.
Lycia Therapeutics is a South San Francisco-based biotechnology firm advancing lysosomal targeting chimeras platform to degrade disease-causing extracellular proteins. Its LYTAC technology addresses targets inaccessible to traditional drugs, developing therapies for neurodegenerative disorders, cancer, and autoimmune diseases. Founded in 2020, the company raised significant venture funding from investors like Versant Ventures and The Column Group.
CellCentric is a Cambridge-headquartered clinical-stage biotechnology company developing p300/CBP inhibitors for cancer therapy. Its lead candidate, inobrodib, entered Phase II trials for multiple myeloma and NRAS-mutant melanoma in 2023. The oral drug targets bromodomain proteins in solid tumors like non-small cell lung cancer. Founded in 2016, CellCentric collaborates with the University of Cambridge on combination regimens with PD-1 inhibitors.
SnapNurse is a per diem staffing platform matching nurses and clinicians with hospitals using Instastaff AI algorithms. Tampa-headquartered since 2018, it handles credentialing, scheduling, and payments for shifts in Florida facilities. SnapNurse serves over 100 healthcare providers, supporting specialties like ICU and ER with mobile booking and timecard approvals.
HQ CountryUnited StatesUnited StatesUnited KingdomUnited States
HQ City
Philadelphia, PA
San Francisco, CA
Cambridge
Atlanta, GA
Deal Date6 Jul 202624 Jun 20265 May 202628 Apr 2026
RoundSeries DSeries DSeries DSeries A
Raised$67M$75M$220Mundisclosed
InvestorsNovartis Venture Fund; Wellington Management; Axil Capital; LG Technology Ventures; HBM Healthcare Investments; Cormorant Asset Management; SymBiosis; 3B Future Health Fund; SR One; Primer Ventures; OrbiMed; Samsung SecuritiesBrandywineGLOBAL; RTW Investments; Balyasny Asset Management; HBM Healthcare Investments; Invus; Eli Lilly; Adage Capital Management; OrbiMed; Janus Henderson Investors; Venrock Healthcare Capital PartnersFidelity; HBM Healthcare Investments; Sofinnova Partners; BrightEdge (American Cancer Society VC unit); Avego Bioscience Capital; RA Capital Management; Forbion Capital Partners; Venrock Healthcare Capital Partners; PfizerInfinitum Asset Management; HBM Healthcare Investments; Suvretta Capital Management; Data Point Capital
Valuationundisclosedundisclosed$900Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all HBM Healthcare Investments investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About HBM Healthcare Investments

When was HBM Healthcare Investments founded?HBM Healthcare Investments was founded in 2001.
Where is HBM Healthcare Investments headquartered?HBM Healthcare Investments is headquartered in Switzerland.
How many employees does HBM Healthcare Investments have?As of today, HBM Healthcare Investments has over 1 employees.
Is HBM Healthcare Investments publicly listed?Yes, HBM Healthcare Investments is a public company listed on SIX Swiss Exchange.
What is the stock symbol of HBM Healthcare Investments?HBM Healthcare Investments trades under HBMN ticker.
Who are competitors of HBM Healthcare Investments?HBM Healthcare Investments main competitors include Grupo Bolivar, FIBRA Macquarie, Generation Capital, L1 Group, Magellan Financial Group, FII Ancar IC, Bure Equity, MFF Capital, Israel Corp, L1 Long Short Fund.
What is the current market cap of HBM Healthcare Investments?HBM Healthcare Investments' current market cap is $2B.
What is the current revenue of HBM Healthcare Investments?HBM Healthcare Investments' last 12 months revenue is $102M.
What is the current EV/Revenue multiple of HBM Healthcare Investments?Current revenue multiple of HBM Healthcare Investments is 21.2x.
What is the current net income of HBM Healthcare Investments?HBM Healthcare Investments' last 12 months net income is $347M.
How many companies HBM Healthcare Investments has acquired to date?HBM Healthcare Investments hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies HBM Healthcare Investments has invested to date?As of July 2026, HBM Healthcare Investments has invested in 80 companies.
What was the last HBM Healthcare Investments investment?On 6th July 2026 HBM Healthcare Investments invested in Fore Biotherapeutics, participating in a $67M Series D round, alongside Novartis Venture Fund, Wellington Management, Axil Capital, LG Technology Ventures, Cormorant Asset Management, SymBiosis, 3B Future Health Fund, SR One, Primer Ventures, OrbiMed, and 1 other investor.
In what companies HBM Healthcare Investments invested in?HBM Healthcare Investments invested in Everest Medicines, Jixing Pharmaceuticals, Harmony Biosciences, Alumis, CellCentric, Odyssey Therapeutics, NiKang Therapeutics, Ambrx, Upstream Bio, Valo Health, Electra Therapeutics, Bluejay Therapeutics, Nuance Biotech, SK Biopharmaceuticals, Ignis Therapeutics, FogPharma, Karius, IO Biotech, VISEN Pharmaceuticals, Jianke, and 60 other companies.

See public comps similar to HBM Healthcare Investments

Lists including HBM Healthcare Investments

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial